IntegenX Awarded Four Qualifying Therapeutic Discovery Project Grants

PLEASANTON, Calif., Nov. 10, 2010 /PRNewswire/ -- IntegenX, Inc. (IXI), a developer of automated DNA and RNA based sample preparation systems, today announced that it has been awarded four grants totaling $976,000 under the Qualifying Therapeutic Discovery Project Program (QTDP). The IntegenX programs focus on developing platforms for DNA sample preparation, next-generation sequencing library preparation, and sample-to-answer analysis of human genotypes.

"We are pleased to receive federal recognition that our platforms have the potential for impacting the development of therapeutics, molecular diagnostics, and discovery of genetic markers that will improve outcomes for patients," said Dr. Stevan Jovanovich, CEO and President of IntegenX. "These awards provide IntegenX with additional support to continue development of our products and to accelerate advancing them to the market."

The QTDP is provided under Section 48D of the Internal Revenue Code, enacted as part of the Patient Protection and Affordable Health Care Act of 2010. Qualifying projects had to show potential to produce new therapies, reduce long-term health care costs, or significantly advance the goal of curing cancer within the next 30 years. Preference was given to projects that showed the greatest potential to create and sustain high-quality, high-paying jobs in the U.S. and advance the country's competitiveness in the fields of life, biological, and medical sciences.

About IntegenX

IntegenX, Inc., headquartered in Pleasanton, CA, is a privately held company that designs, manufactures and markets automated DNA and RNA based sample preparation systems for life sciences, applied sciences, and diagnostics markets. IntegenX products eliminate the most acute pain points affecting widely adopted laboratory workflows. The company's expertise and intellectual property includes its patented MOVe valve technology and proprietary patent pending PrepX reagent kits. The microfluidics technology platform integrates advanced fluidics and robotic capabilities to prepare samples for DNA and RNA sequencing and to produce sample-to-answer performance for DNA-based forensics and human identity (HID) testing, biodefense, and molecular diagnostics applications. The company's first commercial platform, the Apollo 100 System, is used to optimally prepare DNA for Sanger sequencing. IntegenX recently released the Apollo 324 System to integrate the fragmented workflows in next-generation sequencing library preparation. IntegenX has successfully tested a sample-to-answer platform for human DNA identification, slated for commercialization in 2011. For more information, please visit http://www.integenx.com.

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.

SOURCE IntegenX, Inc.